TrialBlood2021

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.

Norbert Schmitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.